Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria

Dupuis, Jehan; Itti, Emmanuel; Rahmouni, Alain; Hémery, François; Gisselbrecht, Christian; Lin, C.; Copie‐Bergman, Christiane; Belhadj, Karim; Gnaoui, Taoufik El; Gaillard, Isabelle; Kuhnowski, Frédérique; Meignan, Michel; Haı̈oun, Corinne

doi:10.1093/annonc/mdn671

Cited by 73 publications

(58 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5][6][7][8][9][10][11] The superiority of PET over computed tomography in identifying active disease after therapy completion has recently led to the revision of response criteria. 32 Several studies have shown that after 1-3 cycles of chemotherapy for aggressive NHL, 3,[5][6][7][8][9][10][11]34 early metabolic changes as documented by early or interim PET scan may be highly predictive of final treatment response and progression-free survival. However, the real benefit of interim PET in aggressive NHL has been questioned recently.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4] In particular, several studies that have evaluated the role of PET as a prognostic tool during chemotherapy have reported its ability to predict outcomes in aggressive NHL. [5][6][7][8][9][10][11] In force of the pivotal role played by PET in staging, restaging, and response evaluation, the International Workshop Criteria for malignant lymphoma 12 have been revised to incorporate the PET data in NHL outcome assessment, but only at the end of therapy.…”

mentioning

confidence: 99%

“…Recent reports of PET evaluation have demonstrated a greater degree of accuracy in early response assessment compared with computed tomography. [5][6][7][8][9][10][11] However, the benefit of midtreatment (or interim) PET evaluation in aggressive NHL is still a matter of debate, 24 and a meta-analysis conducted by Terasawa et al 3 indicated that interim PET has unproven reliability in routine clinical practice.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Zinzani

Gandolfi

Broccoli

et al. 2010

Cancer

View full text Add to dashboard Cite

Herein, we report on direct preparation of macroporous polyimide (PI) films with pores distributing on one side, the method of which relies on sedimentation of ceramic spheres in polyamic acid (PAA) solutions in a gravitational field and imidization of PAA/ceramic spheres mixtures to obtain PI/ceramic spheres hybrid films followed by curing in dilute hydrofluoric (HF) acid. In this strategy, the curing of the hybrid films in HF acid leads to the formation of pores. The introduction of pores makes the room‐temperature dielectric constants of the macroporous films lower than that of pure PI film. Moreover, the macroporous PI films have improved Young's moduli and higher thermal stability in nitrogen atmosphere. © 2007 Wiley Periodicals, Inc. J Appl Polym Sci 104: 261–266, 2007

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Zinzani

Gandolfi

Broccoli

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…PET/CT has become a standard of care in both Hodgkin lymphoma and non-Hodgkin lymphoma as part of the restaging assessment. 38 Patients with a negative PET scan result have an excellent outcome, and multiple studies have shown that FDG-PET performed after treatment is highly predictive of progression-free survival and overall survival in aggressive non-Hodgkin lymphoma [39][40][41][42][43] and follicular lymphoma. 44 PET scans can also be particularly useful in patients with lymphoma who have a residual mass at the completion of therapy.…”

Section: Posttreatment Scans (To Document Remission)mentioning

confidence: 99%

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Ansell

Armitage

2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

The use of sensitive and specific imaging techniques for accurate initial staging and evaluation of response to therapy in patients with lymphoma is essential for their optimal management. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) has emerged as a powerful imaging tool and is being routinely used in staging, response evaluation, and posttreatment surveillance in patients with non-Hodgkin lymphoma and Hodgkin lymphoma. PET/CT is currently widely used in clinical practice, but the established clinical benefit is currently restricted to the posttreatment evaluation of Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Although used in other histologic subtypes and in other clinical situations including response assessment, its impact on patient outcome remains to be demonstrated. We performed a literature search of PubMed from 1999 to 2011 using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. This review addresses the challenges and controversies in the use of PET/CT scans in the management of patients with lymphoma. I n most patients with lymphoma, positron emission tomographic (PET) scans show abnormalities at diagnosis. Normal findings on the scan after therapy is highly predictive of a good prognosis, particularly in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and Hodgkin lymphoma. However, the optimal application of PET scans to the management of all patients with lymphoma remains problematic. The major controversies include the optimal timing of PET scans (for staging, during therapy, after completion of therapy, surveillance in remission), standardization of PET scan interpretation (visual interpretation compared with standard uptake value [SUV] calculation), what constitutes a positive PET scan result, and whether PET scans should be used to direct management (eg, does changing therapy in patients with positive findings on PET change outcome, should biopsies of sites with positive PET results be done routinely before a management change). Although a large body of literature addressing these topics exists, the studies are often difficult to compare, making definitive conclusions on all these issues difficult. The previously published studies often used different designs and variable reporting, making interpretation and comparison of the results difficult. In the early studies particularly, heterogeneous populations with different stages of disease and different histologic subtypes were included, making the clinical applicability of the studies' results difficult. More recent studies focusing on efforts to standardize the conduct and interpretation of PET scans and on riskadapted therapies based on interim PET scan results will, it is hoped, improve the management and outcome of patients with lymphoma. A literature search of PubMed from 1999 to 2011 was performed using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. We highlight the current standard use ...

show abstract

“…complete remission [1]. However, although PET scans are quite sensitive, they are not specific for lymphoma [2][3][4][5][6]. Among the conditions that are also often PET avid and might mimic recurrent lymphoma are other malignancies, sarcoidosis, Wegener's granulomatosis, chronic granulomatous disease, and mycobacterial and aspergillus infections.…”

mentioning

confidence: 99%

Sarcoidosis mimicking recurrent lymphoma

Holdeman

Laurini

et al. 2011

American J Hematol

View full text Add to dashboard Cite

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria

Abstract: The integration of PET in treatment evaluation offers a powerful tool to predict outcome.

Cited by 73 publications

References 17 publications

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Sarcoidosis mimicking recurrent lymphoma

Contact Info

Product

Resources

About

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria

Abstract: The integration of PET in treatment evaluation offers a powerful tool to predict outcome.

Cited by 73 publications

References 17 publications

Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Sarcoidosis mimicking recurrent lymphoma

Contact Info

Product

Resources

About

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma